In addition, PMN-MDSCs with high levels of STAT3 activity and ARG1 expression are strongly related to prostate cancer progression, and STAT3 blockade impairs the immunosuppressive effect of PMN-MDSCs on effector T-cell activity [140]. This evidence concerns the gene STAT3 and prostate carcinoma.